Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Quick Listen: Scrip’s Five Must-Know Things

Corporate Pandemic Impact, Important US Launches And RSV Overview

Executive Summary

Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.

Take a brief audio tour around Scrip’s Five Must-Know Things, in this episode covering major developments in the business week ended 7 August 2020.

Making headlines this time are the corporate impact of the coronavirus pandemic, new launches for depression and lymphoma in the US and an overview of progress in the RSV space.

Stories mentioned in this episode:

(Also see "Merck Outlines COVID-19 Vaccine And Antiviral Plans As Pandemic Dents Q2 Sales" - Scrip, 31 Jul, 2020.)

(Also see "Bayer Q2 Pharma Sales Ravaged By COVID-19" - Scrip, 4 Aug, 2020.)

(Also see "US FDA Opens Door For J&J's Spravato To Another MDD Population" - Scrip, 3 Aug, 2020.)

(Also see "Morphosys/Incyte’s Monjuvi Wins Early US FDA Approval In Second-Line DLBCL" - Scrip, 4 Aug, 2020.)

(Also see "Progress In Pharma’s Slow Battle Against Respiratory Syncytial Virus" - Scrip, 7 Aug, 2020.)

 

Related Content

Topics

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel